Christine S. Rollier
Associate Professor in Vaccinology
- Research Scientist – Team Head
- Preclinical and early clinical novel vaccine development
- Jenner Investigator
Christine Rollier is a senior research scientist in Vaccinology at the Oxford Vaccine Group, leading the Novel Vaccine Development team involved in the creation, design, preclinical and early clinical studies of new and improved vaccines against bacterial diseases and infectious diseases affecting children.
She studied biochemistry and obtained her PhD at the University of Lyon I in 2000, with a focus on DNA immunization as a therapeutic approach against chronic Hepatitis B Virus infection. She trained in immunology, specialising in vaccine development at Institut National de la Sante et Recherche Medicale (INSERM), Lyon, France. She proceeded to work on novel vaccine development and cellular immunity against Hepatitis C Virus chronic infection at the Biomedical Primate Research Center, The Netherlands for five years, before joining the Jenner Institute at the University of Oxford in 2007 as a senior immunologist, to work on improvements of vaccine vectors against malaria. She joined the Oxford Vaccine group in 2010, bringing her expertise of viral vectored vaccine platform and preclinical research, to work on meningococcal and preclinical vaccine development.
Her current research activities, funded by the Medical research Council, Innovate UK, the Oxford Biomedical Research Centre, and several charities, include the conception, design, pre-clinical and early clinical development of new and improved vaccines against bacterial infections such as caspular group B meningococcus, plague, Q fever, enteric fever, pertussis and Respiratory Syncitial Virus.
Vaccination with the Staphylococcus aureus secreted proteins EapH1 and EapH2 impacts both S. aureus carriage and invasive disease.
Elshina E. et al, (2019), Vaccine, 37, 502 - 509
Heterogeneous early immune responses to the S. aureus EapH2 antigen induced by gastrointestinal tract colonisation impact the response to subsequent vaccination.
Flaxman A. et al, (2019), Vaccine, 37, 494 - 501
Optimization of Zika virus envelope protein production for ELISA and correlation of antibody titers with virus neutralization in Mexican patients from an arbovirus endemic region.
Kim YC. et al, (2018), Virol J, 15
Natural immunity against capsular group X N. meningitidis following an outbreak in Togo, 2007.
Norheim G. et al, (2018), Vaccine
Development of persistent gastrointestinal S. aureus carriage in mice
Wyllie DH. et al, (2017), Scientific Reports